uploads///syringe _

A Look at the Upside Potential of AstraZeneca Stock

By

May. 30 2018, Updated 6:30 p.m. ET

Company overview

AstraZeneca (AZN) is a global innovation-focused biopharmaceutical company with a presence in more than 100 countries. In this series, we’ll analyze the performance of AstraZeneca’s key products in each category, including Lynparza, Tagrisso, and Imfinzi.

Article continues below advertisement

Analysts’ ratings

In May, four of the six analysts covering AstraZeneca (AZN) gave the stock a “buy” or a higher rating, and two analysts gave AZN stock a “hold” rating. The mean rating for the stock is ~1.8 with a target price of $39.09. This implies an upside potential of 7.3% over the stock’s trading price level of $36.44 on May 29.

Peer ratings

In May, 16 of the 21 analysts covering Merck (MRK) in May gave the stock a “buy” or higher rating, and five analysts gave it a “hold” rating. The mean rating for the stock is ~2.0 with a target price of $69.06.

Of the 20 analysts covering Eli Lilly (LLY) in May, 12 analysts gave the stock a “buy” or higher rating, seven analysts gave it a “hold” rating, and one analyst gave the stock a “sell” rating. The mean rating for the stock is ~2.2 with a target price of $90.89.

In May, 11 of the 22 analysts covering Pfizer (PFE) gave the stock a “buy” or higher rating, nine analysts gave the stock a “hold” rating, and two analysts gave Pfizer stock a “strong sell” rating. The mean rating for the stock is ~2.6 with a target price of $39.60.

In the next part of this series, we’ll take a look at the performance of AstraZeneca’s oncology products. Throughout this series, we’ll discuss its year-over-year product growth rates unless otherwise stated.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.